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 T0 T3 T6 T9 
ETP (nM min) 529.25±98.64     558.82±114.67 548.57±93.38 533.04±103.15 
PH (nM) 132.77±44.9  103.4±44.9 108.0±36.7 132.0±44.6 
Ematologia-Policlinico Universitario di Palermo 
Background: Cryopreservation of platelets (PLTs) at -80°C with 
dimethyl sulfoxide (DMSO) can extend their shelf life up to 2 years. 
Cryopreserved PLTs (CRY-PLTs) are reported to have a greater in vivo 
hemostatic effect than liquid-stored PLTs. Aims of this study were: i.to 
evaluate the thrombin generation potential of buffy coat derived 
cryopreserved PLTs (CRY BC-PLT) in comparison with fresh buffy coat 
derived platelets concentrates; ii.to determine the efficacy and safety of 
CRY-PLTs transfusion in hematological patients with severe 
thrombocytopenia. 
 
Materials and methods: Buffy coat derived platelets were obtained from 5 buffy coats and pooled. The final PLTs 
concentrates were leukoreduced by filtration and transferred to a 650 mL patented cryopreservation kit (Promedical 
®) which allowed mixing with DMSO 25% in a closed system and following removal of supernatant without further 
manipulations. BC-PLTs were washed prior freezing with removal of at least 84% supernatant solution, suspended in 
homologous plasma from 1 of the 5 donors to a final concentration of 200 mL and frozen at – 80°.CRY- BC PLTs 
were preserved at -80°C with 6% DMSO . A system of 3 accessory  bags directly connected to the mother bag was 
adopted for the in vitro study to avoid repeated freezing/thawing of samples at each time point after cryopreservation. 
In vitro assays were performed before freezing and at 3,6 and 9 months after thawing .Before assay, CRY-BC PLT 
were thawed at 37°C and diluted in plasma to adjust to 300× 10
9
/L PLTs. Fresh BC PLTs underwent the same 
dilution to adjust to 300× 10
9
/L PLTs. Thrombin generation (TGA) was tested in CRY BC-PLTs and compared to TG 
potential of fresh BC PLTs. TGA was triggered by the addition of 0.5 pmol/L of recombinant human tissue factor. 
Endogenous thrombin potential (ETP) and peak height (PH) were determined. Flow Cytometry assays for  PLTs 
activation markers and thromboelastography were also determined on each sample. CRY-BC PLTs ,separately 
prepared according to the above described method for in vivo study, were infused in five  hematological patients with 
acute leukemia (AL) and severe thrombocytopenia (PLTs <10× 10
9
/L) participating to the trial NCT02032134.CRY-
BC PLTs were transfused to control epistaxis (n=2) and for prophylaxis (n=3). Patients were observed up to 7 days 
after infusion and the occurrence of any side effect was registered. An increase in PLTs count was observed only in 
one case, under prophylaxis, but bleeding was successfully controlled or prevented in all cases. Plasma from patients 
transfused with CRY-BC PLTs was tested for TGA pre-treatment and 24 hours after treatment. 
 
Results Fourty nine BC-PLTs from 245 healthy volunteer donors (145 
males and 100 females, mean age: 48.16.±18.91) were prepared, 
cryopreserved and analyzed up to 9 months after storage. Cryopreserved 
PLTs show a good thrombin generation potential that is stably maintained 
up to 9 months after cryopreservation [ETP (nM min): 529.25±98.64 at T0, 
558.82±114.67 at T3, at 548.57±93.38 T6 and 533.04±103.15 at T9 
months, respectively; PH(nM): 132.77±44.9 at T0, 103.4±44.9 at T3, 
108.0±36.7at T6 and 132.0±44.6 at T9 months ,respectively]. At TGA, 
fresh BC-PLTs (n=35) had a mean ETP of 760.13±130.11,PH was 
138.9±40.2. Thrombin generation of CRY-BC PLTs is comparable to fresh 
BC-PLTs, even if slightly decreased. Infusion of CRY-BC PLT (1U) was 
effective in controlling mucosal bleeding (epistaxis) in two patients  with 
AL and  severe thrombocytopenia. CRY-PLT were also effective when 
administered for prophylaxis in 3 patients with very low platelets count 
secondary to chemotherapy. In vivo, thrombin generation is stably 
maintained up to  24 hours after infusion of 1 Unit of CRY-BC PLTs, 
without any adverse effect (mean ETP pre-treatment was: 414.13160.60, 
24 hours after transfusion : 326.95152.54).CRY-BC PLTs were safe and 
they did not determine any thrombotic event.At flow-cytometry, CRY-BC 
PLTs expressed higher activation markers (CD62P,CD63)  than fresh BC 
PLTs. CRY-BC PLTs are able to significantly decrease the time to clot 
formation and clot strength, as measured also  by thromboelastography. 
CRY-BC PLTs activation/deterioration is accompanied by an effective 
hemostatic in vivo function. 
 
Conclusions: Cryopreserved PLTs have an enhanced hemostatic activity and a good thrombin 
generation potential. They are effective and safe in preventing and controlling bleeding, being 
available in emergency/urgency settings also for patients with acute leukemia and severe 
thrombocytopenia. 
 
 
